2. Signaling Pathways
  3. Others
  4. Drug Derivative

Drug Derivative

Drug derivative

 

Drug Derivative Related Products (917):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-123695
    5-HT4 antagonist 3
    5-HT4 antagonist 3 is an active compound.
    5-HT4 antagonist 3
  • HY-169038
    11(Z),14(Z)-Eicosadienoic acid ethanolamide
    11(Z),14(Z)-Eicosadienoic acid ethanolamide (Compound 3) is an ethanolamide-conjugated form of 11(Z),14(Z)-Eicosadienoic acid (HY-149589). 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC50 value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions.
    11(Z),14(Z)-Eicosadienoic acid ethanolamide
  • HY-135479
    A28695B
    A28695B is an active compound.
    A28695B
  • HY-122250
    LY 288601
    LY 288601 is a potent anticancer agent.
    LY 288601
  • HY-171044
    Anticancer agent 261
    Anticancer agent 261 (compound 13) is an anticancer compound.
    Anticancer agent 261
  • HY-111301
    FR217840
    FR217840 is an active compound.
    FR217840
  • HY-124245
    3-Hydroxy desloratadine
    3-Hydroxy desloratidine is a metabolite of Desloratidine.
    3-Hydroxy desloratadine
  • HY-116167
    RY 024
    RY 024 is an active compound.
    RY 024
  • HY-W659059
    N-Methyl-1-phenylpropan-1-amine hydrochloride
    N-Methyl-1-phenylpropan-1-amine hydrochloride is structurally categorized as a benzylamine.
    N-Methyl-1-phenylpropan-1-amine hydrochloride
  • HY-101657
    Clocoumarol
    Clocoumarol is an active compound.
    Clocoumarol
  • HY-136997
    M-5MPEP
    M-5MPEP is an active compound.
    M-5MPEP
  • HY-113594
    ICI 200355
    ICI 200355 is an active compound.
    ICI 200355
  • HY-116487
    R-18893
    R-18893 is an active compound.
    R-18893
  • HY-133623
    1,1,1-Tribromoacetone
    1,1,1-Tribromoacetone is a tribromide product based on bromoacetone.
    1,1,1-Tribromoacetone
  • HY-W269511
    NW-1689
    NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research.
    NW-1689
  • HY-117850
    TAK 187
    TAK 187 is an active compound.
    TAK 187
  • HY-119319
    LLP6
    LLP6 is an active compound.
    LLP6
  • HY-136628
    RU 25434
    RU 25434 is an active compound.
    RU 25434
  • HY-120853
    SR-4326
    SR-4326 is an active compound.
    SR-4326
  • HY-W674641
    WAY-648936
    		≥98.0%
    WAY-648936 is an active molecule.
    WAY-648936